Alithea Genomics, a leader in RNA sequencing and transcriptomics, has introduced its MERCURIUS™ Full-Length DRUG-seq library preparation technology. This groundbreaking innovation combines massive sample multiplexing, an extraction-free workflow, and full transcript coverage, creating a unique RNA-seq workflow. The technology is compatible with both 96- and 384-well plate formats, enabling up to 384 full-length RNA-seq library preparations in a single tube, all without the need for RNA isolation.
Alithea Genomics, a leader in RNA sequencing and transcriptomics, has launched its MERCURIUS™ Full-Length DRUG-seq library preparation technology. This innovative solution offers significant advancements over traditional 3’ mRNA-seq methods by enabling the detection of a wider range of gene features, including different transcripts, isoforms, splicing variants, and alternative promoters. According to Riccardo Dainese, PhD, CEO and co-founder of Alithea Genomics, Full-Length DRUG-seq offers a more comprehensive view of gene expression, allowing scientists to conduct large-scale compound screening based on full-length RNA sequencing. This breakthrough could lead to new drug discoveries targeting gene isoforms and splicing mechanisms.
MERCURIUS™ Full-Length DRUG-seq is designed to prepare Illumina-compatible RNA sequencing libraries for up to 384 samples in a cost-effective and time-efficient manner. Unlike the standard DRUG-seq kit, which only provides 3′ coverage, this technology enables full-length transcript coverage. It can detect over 40,000 unique transcripts with just 4 million reads per sample, achieving similar results to non-multiplexed gold standard techniques. Additionally, it provides deeper insights into gene isoforms, splicing variants, and alternative promoters.
Dr. Dainese also noted that the launch of Full-Length DRUG-seq is just the beginning. Alithea Genomics plans to release more innovative products and services throughout 2025. These will continue to focus on sample multiplexing and extraction-free procedures, further improving the processing speed and versatility across different sample types.
Alithea is now accepting orders for the MERCURIUS™ Full-Length DRUG-seq kits and services, which are expected to help accelerate drug discovery and development processes by providing more detailed insights into RNA biology.
RNA sequencing (RNA-seq) is a powerful technique that examines the quantity and sequence of RNA in biological samples. This analysis helps scientists understand which genes are activated or suppressed in specific conditions, such as disease states or responses to drugs. By capturing this data, RNA-seq can guide decision-making in drug discovery and development.
Alithea Genomics specializes in massively multiplexed RNA-seq library preparation solutions. Their technologies, like BRB-seq (Bulk RNA Barcoding and Sequencing), make RNA sequencing more affordable and efficient by enabling the preparation of hundreds of samples in a single tube, reducing the need for expensive reagents and manual labor. This allows researchers to generate valuable data at a fraction of the cost and time traditionally required.
Founded in 2020 at EPFL in Lausanne, Switzerland, Alithea Genomics is committed to advancing RNA sequencing technologies to improve research and drug development. Through its innovative solutions, Alithea aims to provide the tools necessary to discover new biomarkers and drugs, ultimately transforming healthcare.
